| Bret
Barnhizer and Dana Allen Elected to NanoLogix Board of Directors
|
February
27, 2007:, SHARON, PA -- (MARKET WIRE) -- NanoLogix, Inc. (PINKSHEETS:
NNLX) announces the election of Bret Barnhizer and Dana Allen
to its Board of Directors. Mr. Barnhizer will serve as Director-At-Large
with Mr. Allen serving as Vice President of Strategic Partnering.
The addition of Mr. Barnhizer and Mr. Allen expands the number
of directors on the NanoLogix board to five.
Bret Barnhizer
For more than 25 years, Bret Barnhizer has provided engineering,
operations management, and project management services to Chevron,
BP, Unocal, Occidental Petroleum, and others in the U.S., Europe,
Africa, and Asia. Mr. Barnhizer has managed and been involved
in projects of varied scope, ranging from 40 million to over 500
million dollars in value.
Dana Allen
Dana Allen has 26 years of business experience in numerous industries
and sectors; Mr. Allen was the Founder, Chairman and CEO of Sequoia
Data Corp. (1987-1996); Vice President then later Chairman, CEO
and President of TMSSequoia (a public co.) (1996-1999) where he
was granted 8 patents for various inventions; Co-Founder and Chairman
of NewsMax (1998-2000), President of American Investigator Television
(2000-2001). Mr. Allen is currently President of Sequoian Technologies,
an invention creation and marketing firm whose primary business
is to market patents by Mr. Allen and others in a broad range.
The first patents to be filed relate to reducing emissions approximately
90% in 2-Stroke engines and a new 4 Stroke Engine Cycle method
that will improve fuel economy.
"We are extremely pleased to welcome Bret and Dana to the
NanoLogix Board of Directors," said CEO Mitchell Felder,
M.D. "I anticipate that their individual professional experience,
business acumen and personal integrity will enable them to contribute
meaningfully to the further formation of our strategy and to serve
NanoLogix shareholders well."
"I am excited to join the Nanologix team," said Director,
Dana Allen. "It is the most technology rich company of its
size I have ever seen. The Board is focusing on commercializing
the company's valuable patents and technologies. We see the opportunity
for these technologies having profound positive effects for the
world in addition to their commercial value."
About NanoLogix, Inc.
NanoLogix is an industry innovator in the research, development
and commercialization of nano-biotechnologies, applications and
processes. The Company owns or has the rights to 32 patented technologies.
The Company is currently focused on the production of hydrogen
from agricultural feedstock, industrial wastewater and municipal
waste streams to create new sources of energy. NanoLogix is presently
operating a hydrogen bioreactor at Welch's Food and has recently
signed an agreement with the City of Erie Wastewater Treatment
Plant for a prototype bioreactor installation. Additionally, NanoLogix
develops and markets diagnostic test kits for use in early detection
of infectious human diseases such as cancer, cystic fibrosis and
AIDS, and owns a patent for the non-toxic induction of apoptosis
('cell suicide') for the treatment of cancer. For more information
on the Company, visit .nanologixinc.com.
This press release contains statements, which may constitute "forward-looking
statements" within the meaning of the Securities Act of 1933
and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations
of NanoLogix, Inc., and members of its management as well as the
assumptions on which such statements are based. Prospective investors
are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated
by such forward-looking statements. The Company undertakes no
obligation to update or revise forward-looking statements to reflect
changed assumptions, the occurrence of unanticipated events or
changes to future operating results.
Contact:
Investor Relations
Bret Barnhizer
724-346-1302
